Ignite Creation Date:
2024-05-06 @ 7:00 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05862766
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-26
First Post:
2023-05-08
Brief Title:
Isatuximab in Lung Transplant Recipients
Sponsor:
NYU Langone Health
Organization:
NYU Langone Health
Study Overview
Official Title:
A Pilot Study of Isatuximab in Addition to Standard Therapy for Desensitization or Antibody-mediated Rejection in Lung Transplant Recipients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety and feasibility of adding isatuximab to standard of care therapies in patients who will receive a lung transplant but have significant antibodies against the donor desensitization or patients who have previously received a lung transplant and develop antibodies against the donor antibody-mediated rejection AMR The study will compare the impact of isatuximab on the recurrence of antibodies after they have been removed from the blood by a process known as plasmapheresis that is standard of care for this condition The use of isatuximab in lung transplant recipients is investigational meaning it is not Food and Drug Administration FDA approved for use in lung transplant recipients This study is a pilot study investigating the feasibility and safety of isatuximab in lung transplant patients Isatuximab is an FDA approved drug indicated for the treatment of multiple myeloma It may also be useful for transplant recipients with antibodies against the donor because it eliminates the cells that make antibodies
Detailed Description:
This dual-arm pilot study will enroll approximately 6 patients undergoing lung transplantation at NYU Langone Health who are either receiving peri-transplant desensitization or who are admitted for treatment of AMR All patients will be treated with standard-of-care consisting of plasmaspheresis IVIG and rituximab Additionally the experimental agent isatuximab will be added to this treatment protocol The patients will first receive 4 weekly doses of isatuximab followed by 4 bi-weekly doses total 8 doses given over 12 weeks Patients will be followed with standard-of-care immunologic assessment consisting of weekly DSA assessment and flow cytometry crossmatch only in the desensitization arm Additionally patients undergoing peri-transplant desensitization will have a bone marrow biopsy with pathologic examination and cell counts performed at the time of transplant and repeated at the 30-day bronchoscopy to assess for plasma cell elimination
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None